Molecular aspects of resistance to antitumor platinum drugs

Drug Resistance Updates

Volumn 5, Issue 3-4, 2002, Pages 147-161

  Brabec, Viktor ^a   Kasparkova, Jana ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

Author keywords

Antitumor; Cisplatin; Cross links; Damaged DNA binding proteins; DNA; DNA repair; Oxaliplatin; Trinuclear platinum drugs

Indexed keywords

ANTINEOPLASTIC AGENT; BBR 3464; CELL PROTEIN; CISPLATIN; DNA; DNA BINDING PROTEIN; NUCLEOTIDE; OXALIPLATIN; PLATINUM; SULFUR;

ANTINEOPLASTIC ACTIVITY; CHEMICAL STRUCTURE; DNA ADDUCT; DNA MODIFICATION; DRUG DNA BINDING; DRUG INACTIVATION; DRUG MECHANISM; EXCISION REPAIR; MISMATCH REPAIR; MOLECULAR RECOGNITION; PRIORITY JOURNAL; REVIEW;

CISPLATIN; DNA ADDUCTS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR BIOLOGY; ORGANOPLATINUM COMPOUNDS;

EID: 0036618858     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(02)00047-X     Document Type: Review

References (148)

1. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells
2. Post-replication repair in an excision defective strain of Escherichia coli following treatment with cis-dichlorodiammineplatinum(II)
3. Mechanism of toxicity of platinum(II) compounds in repair-deficient strains of Escherichia coli
4. DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective
5. L-Methionine increases the rate of reaction of 5′-guanosine monophosphate with anticancer drug cisplatin: Mixed-ligand adducts and reversible methionine binding
6. Effect of cis-platinum(II)diamminodichloride on wild type and deoxyribonucleic acid repair-deficient mutants of Escherichia coli
7. Reactions of the UvrABC excision nuclease with DNA damaged by diammine-dichloroplatinum(II)
8. Does resistance to apoptosis affect clinical response to antitumor drugs?
9. Chemistry and structural biology of 1,2-interstrand adducts of cisplatin
10. DNA modifications by antitumor platinum and ruthenium compounds: Their recognition and repair
11. DNA modifications by a novel bifunctional trinuclear platinum Phase I anticancer agent
12. Biophysical studies of the modification of DNA by antitumour platinum coordination complexes
13. DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues
14. The in vitro more efficiently repaired cisplatin adduct cis-PtGG is in vivo a more mutagenic lesion than the relative slowly repaired cis-PtGCG adduct
15. Base-pair substitution hotspots in GAG and GCG nucleotide sequences in E. coli K-12 induced by cis-diamminedichloroplatinum(II)
16. Apoptosis: Mediator or mode of cell killing by anticancer agents?
17. Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin
18. Repair synthesis by human cell extracts in cisplatin-damaged DNA is prefentially determined by minor adducts
19. Cisplatin: From DNA damage to cancer chemotherapy
20. TATA binding protein discriminates between different lesions on DNA, resulting in a transcription decrease
21. Activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplatin: Cytotoxicity and induction and gene-specific repair of DNA lesions
22. Mutagenic activity of some platinum complexes with monodentate and bidentate amines
23. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer
24. Cellular responses to cisplatin: The roles of DNA-binding proteins and DNA repair
25. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts
26. Cisplatin and adriamycin resistance are associated with MutL alpha and mismatch repair deficiency in an ovarian tumor cell line
27. 6-methylguanine
28. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes
29. Characterization of bifunctional adducts produced in DNA by trans-diamminedichloroplatinum(II)
30. Biological activity of platinum complexes containing chiral centers on the nitrogen or carbon atoms of a chelate diamine ring
31. Polynuclear charged platinum compounds as a new class of anticancer agents: Toward a new paradigm
32. Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells
33. Adducts of the anfitumor drug cis-diamminedichloroplatinum(II) with DNA: Formation, identification, and quantitation
34. Loss of DNA mismatch repair due to knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin
35. The role of DNA mismatch repair in platinum drug resistance
36. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair
37. Cross-link repair in human cells and its possible defect in Fanconi's anemia cells
38. NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) adduct d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin
39. Anticancer activity of cisplatin and related complexes
40. Repair of platinum-DNA lesions in E. coli by a pathway which does not recognize DNA damage caused by MNNG or UV light
41. Clinical perspectives on platinum resistance
42. Is cisplatin-induced cell death always produced by apoptosis?
43. Metals in medicine
44. Repair and transcription-collision or collusion
45. Mechanisms of cisplatin (cis-diamminodichloroplatinum II)-induced cytotoxicity and genotoxicity in yeast
46. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin
47. In vitro studies on the mechanisms of oxaliplatin resistance
48. Strand-specific binding of RPA and XPA to damaged duplex DNA
49. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease
50. Structure, recognition, and processing of cisplatin-DNA adducts
51. Mechanism of action of platinum cytostatics on bacterial cells
52. Inactivation effect of platinum(II) compounds on strains of Escherichia coli
53. 2] and cisplatin in Escherichia coli
54. The dual role model for p53 in maintaining genomic integrity
55. The effects of cis- platinum(II)diamminodichloride, UV light and N-methyl-N′-nitro-N-nitrosoguanidine on Escherichia coli: Plasmid mediated resistance to mutagens
56. Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes
57. Metal antitumor compounds: The mechanism of action of platinum complexes
58. Recent insights into platinum drug resistance in cancer
59. Molecular mechanisms involved in cisplatin cytotoxicity
60. Kinetic studies of the TATA-binding protein interaction with cisplatin-modified DNA
61. Mechanisms of resistance to cisplatin
62. Recognition of cisplatin adducts by cellular proteins
63. Cisplatin adducts inhibit 1,N-6-ethenoadenine repair by interacting with the human 3-methyladenine DNA glycosylase
64. Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins
65. Different recognition of DNA modified by antitumor cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53
66. Preclinical perspectives on platinum resistance
67. Antitumor activity of 1,2-diamminocyclohexane-platinum complexes against Sarcoma 180 ascites form
68. Modeling multi-component protein-DNA complexes: The role of bending and dimerization in the complex of p53 dimers with DNA
69. DNA adducts of cisplatin, transplatin and platinum-intercalating drugs
70. Repair of damaged DNA by Arabidopsis cell extract
71. What is the "best" platinum: Cisplatin, carboplatin, or oxaliplatin?
72. DNA interactions of antitumor cisplatin analogs containing enantiomeric amine ligands
73. Recognition of major DNA intrastrand cross-links of enantiomeric antitumor cisplatin analogs by HMG box proteins and nucleotide excision repair of these adducts
74. Twenty years of p53 research: Structural and functional aspects of the p53 protein
75. The HMG-domain protein Ixr1 blocks excision repair of cisplatin-DNA adducts in yeast
76. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin
77. Oxaliplatin in practice
78. Double-check probing of DNA bending and unwinding by XPA-RPA: An architectural function in DNA repair
79. Rational design of platinum chemotherapeutic drugs: Hydrophobicity increases cytotoxicity
80. Analysis of incision sites produced by human cell extracts and purified proteins during nucleotide excision repair of a 1,3-intrastrand d(GpTpG)-cisplatin adduct
81. Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts
82. 2]. Metabolite of the anticancer drug cisplatin
83. T4 endonuclease VII cleaves DNA containing a cisplatin adduct
84. p53-induced DNA bending and twisting: p53 tetramer binds on the outer side of a DNA loop and increases DNA twisting
85. Role of the DNA mismatch repair proteins in the recognition of platinum DNA adducts
86. Studies of platinum(II) methionine complexes-metabolites of cisplatin
87. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
88. Clinical status of cisplatin, carboplatin, and other platinum-based antitumor drugs in cisplatin
89. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins
90. Effects of a novel trinuclear platinum complex in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines: Interference with cell cycle progression and induction of apoptosis
91. The general transcription factors of RNA polymerase II
92. The other function of DNA photolyase: Stimulation of excision repair of chemical damage to DNA
93. Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality
94. New cisplatin analogues - On the way to better antitumor agents
95. Replication protein A (RPA) binding to duplex cisplatin-damaged DNA is mediated through the generation of single-stranded DNA
96. Xeroderma pigmentosum complementation group A protein (XPA) modulates RPA-DNA interaction via enhanced complex stability and inhibition of strand separation activity
97. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer
98. Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum(II)
99. Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II)
100. High antitumor activity of a novel multinuclear platinum complex against cisplatin-resistant p53 mutant human tumors
101. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts
102. Why does cisplatin reach guanine-N7 with competing S-donor ligands avaiable in the cell?
103. Platinum-sulfur interactions involved in antitumor drugs, rescue agents, and biomolecules in cisplatin
104. In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR 3464 in neuroblastoma
105. Restoration of wild-type p53 activity enhances the sensitivity of pleural metastasis to cisplatin through an apoptotic mechanism
106. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells
107. Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs
108. Involvement of glutathione in cis-platinum toxicity in Escherichia coli K12
109. DNA excision repair
110. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells
111. Apoptosis is critical for drug response in vivo
112. The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin
113. Clinical and pharmacological phase I study with accelerated titration design of a daily five times schedule of BBR3464, a novel cationic triplatinum complex
114. Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity - Role of G2 arrest and DNA double-strand breaks
115. 2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex
116. An intrastarand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts
117. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin
118. Overcoming cisplatin resistance: Design of novel hydrophobic platinum compounds
119. Effects of cis-diamminedichloroplatinum(II) on Escherichia coli and bacteriophage systems
120. Solution structure of a DNA duplex containing a cis-diammineplatinum(II) 1,3-d(GTG) intrastrand cross-link, a major adduct in cells treated with the anticancer drug carboplatin
121. p53 tagged sites from human genomic DNA
122. Cisplatin-DNA adducts inhibit translocation of the Ku subunits of DNA-PK
123. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts
124. 2+ model adducts
125. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy
126. Nucleotide excision repair in E. coli
127. Preparation, characterization, cytotoxicity, and mutagenicity of a pair of enantiomeric platinum(II) complexes with the potential to bind enantioselectively to DNA
128. Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP
129. Uvr excision repair protein complex of Escherichia coli binds to the convex side of a cisplatin-induced kink in the DNA
130. Analysis of UvrABC endonuclease reaction intermediates on cisplatin-damaged DNA using mobility shift gel electrophoresis
131. In vitro studies on genotoxicity and cytotoxicity of the anticancer drugs cisplatin and cofplaton, a caffeine-8-ether plus cisplatinum compound
132. HPLC determination of binding of cisplatin to DNA in the presence of biological thiols: Implications of dominant platinum-thiol binding to its anticancer action
133. New cisplatin analogs in development: A review
134. Oxaliplatin - A review of its use in the management of metastatic colorectal cancer
135. Current status of platinum-based antitumor drugs
136. DNA repair in eukaryotes
137. DNA damage recognition and nucleotide excision repair in mammalian cells
138. Oxaliplatin-induced damage of cellular DNA
139. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA
140. Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins
141. The response of cellular proteins to cisplatin-damaged DNA
142. Repair of cisplatin-DNA adducts by the mammalian excision nuclease
143. MutS preferentially recognizes cisplatin- over oxali-platin-modified DNA
144. Multiple pathways of recombination define cellular responses to cisplatin
145. Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair of DNA intrastrand cross-links of novel antitumor trinuclear platinum complex BBR3464
146. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor
147. Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms
148. Proteins that specifically recognize cisplatin-damaged DNA: A clue to anticancer activity of cisplatin